LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer

Abstract

Hypoxia and aberrant activation of epidermal growth factor receptor (EGFR) are considered important features of various malignancies. However, whether hypoxia can directly trigger EGFR activation and its clinical implications remain unclear. In this study, we demonstrated that in oral cancer, a typical hypoxic tumor, hypoxia can induce chronic but constitutive phosphorylation of wild-type EGFR in the absence of ligands. Oral cancer cell lines exhibit different EGFR phosphorylation responses to hypoxia. In hypoxic HN4 and HN6 cells, ubiquitination-mediated endocytosis, lysosomal sorting, and degradation lead to low levels of EGFR phosphorylation. However, in CAL-27 and HN30 cells, a novel HIF-1α-induced long noncoding RNA (lncRNA), EUDAL, can compete with the E3 ligase/adaptor complex c-Cbl/Grb2 for binding to EGFR, stabilizing phosphorylated EGFR (pEGFR) and resulting in sustained activation of EGFR and its downstream STAT3/BNIP3 signaling. STAT3/BNIP3-mediated autophagy leads to antitumor drug resistance. A high EUDAL/EGFR/STAT3/autophagy pathway activation predicts poor response to chemotherapy in oral cancer patients. Collectively, hypoxia can induce noncanonical ligand-independent EGFR phosphorylation. High EUDAL expression facilitates sustained EGFR phosphorylation in hypoxic tumor cells and leads to autophagy-related drug resistance.

References

[1] KalyankrishnaS, GrandisJR. Epidermal growth factor receptor biology in head and neck cancer. J. Clin. Oncol., 2006, 24: 2666-2672.

[2] SchlessingerJ. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell, 2002, 110: 669-672.

[3] EndresNF, et al.. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell, 2013, 152: 543-556.

[4] DittmannK, et al.. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem., 2005, 280: 31182-31189.

[5] ZwangY, YardenY. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J., 2006, 25: 4195-4206.

[6] ShanY, et al.. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell, 2012, 149: 860-870.

[7] ChakrabortyS. Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. Nat. Commun., 2014, 55811.

[8] GaoJ, UlekleivCH, HalstensenTS. Epidermal growth factor (EGF) receptor-ligand based molecular staging predicts prognosis in head and neck squamous cell carcinoma partly due to deregulated EGF-induced amphiregulin expression. J. Exp. Clin. Cancer Res., 2016, 35151.

[9] LiA, et al.. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. J. Cancer Res. Clin. Oncol., 2020, 146: 1737-1749.

[10] BenharM, EngelbergD, LevitzkiA. Cisplatin-induced activation of the EGF receptor. Oncogene, 2002, 21: 8723-8731.

[11] KobayashiS, et al.. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2005, 352: 786-792.

[12] LynchTJ, et al.. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350: 2129-2139.

[13] ZhouCC, et al.. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N. Engl. J. Med., 2023, 389: 2039-2051.

[14] HanahanD, WeinbergRA. Hallmarks of cancer: the next generation. Cell, 2011, 144: 646-674.

[15] JingX, et al.. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol. Cancer, 2019, 18157.

[16] BhandariV, et al.. Molecular landmarks of tumor hypoxia across cancer types. Nat. Genet., 2019, 51: 308-318.

[17] MamoM, et al.. Hypoxia alters the response to anti-EGFR therapy by regulating EGFR expression and downstream signaling in a DNA methylation–specific and HIF-dependent manner. Cancer Res., 2020, 80: 4998-5010.

[18] RegoRL, et al.. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br. J. Cancer, 2010, 102: 165-172.

[19] BhanA, SoleimaniM, MandalSS. Long noncoding RNA and cancer: a new paradigm. Cancer Res., 2017, 77: 3965-3981.

[20] SchmittAM, ChangHY. Long noncoding RNAs in cancer pathways. Cancer Cell, 2016, 29: 452-463.

[21] SantiniJ, et al.. Characterization, quantification, and potential clinical-value of the epidermal growth-factor receptor in head and neck squamous-cell carcinomas. Head Neck, 1991, 13: 132-139.

[22] MokTS, et al.. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med., 2009, 361: 947-957.

[23] BorgeaudM, et al.. Unveiling the landscape of uncommon EGFR mutations in NSCLC—a systematic review. J. Thorac. Oncol., 2024, 19: 973-983.

[24] SigismundS, et al.. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev. Cell, 2008, 15: 209-219.

[25] SigismundS, et al.. Threshold-controlled ubiquitination of the EGFR directs receptor fate. EMBO J., 2013, 32: 2140-2157.

[26] BissonN, et al.. Selected reaction monitoring mass spectrometry reveals the dynamics of signaling through the GRB2 adaptor. Nat. Biotechnol., 2011, 29: 653-658.

[27] HaglundK, et al.. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat. Cell Biol., 2003, 5: 461-466.

[28] SchitoL, SemenzaGL. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer, 2016, 2: 758-770.

[29] UribeML, MarroccoI, YardenY. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers, 2021, 132748.

[30] SchmittNC, TrivediS, FerrisRL. STAT1 activation is enhanced by cisplatin and variably affected by EGFR inhibition in HNSCC cells. Mol. Cancer Ther., 2015, 14: 2103-2111.

[31] BanerjeeK, ResatH. Constitutive activation of STAT3 in breast cancer cells: a review. Int. J. Cancer, 2016, 138: 2570-2578.

[32] XueH, et al.. A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3–MIR155–3p-CREBRF pathway. Autophagy, 2016, 12: 1129-1152.

[33] MengJ, et al.. ID1 confers cancer cell chemoresistance through STAT3/ATF6-mediated induction of autophagy. Cell Death Dis, 2020, 11137.

[34] ZhangJ, NeyPA. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ., 2009, 16: 939-946.

[35] MilaniM, et al.. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with bortezomib. Cancer Res., 2009, 69: 4415-4423.

[36] LeeJG, et al.. Autophagy contributes to the chemo-resistance of non-small cell lung cancer in hypoxic conditions. Respir. Res, 2015, 16138.

[37] NukagaS, et al.. Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors. Cancer Res., 2017, 77: 2078-2089.

[38] MaycotteP, et al.. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res., 2014, 74: 2579-2590.

[39] OnoM, KuwanoM. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res., 2006, 12: 7242-7251.

[40] GuoG, et al.. Ligand-independent EGFR signaling. Cancer Res., 2015, 75: 3436-3441.

[41] ZhangX, GureaskoJ, ShenK, ColePA, KuriyanJ. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell., 2006, 125: 1137-1149.

[42] LiuH, ZhangB, SunZ. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. Cancer Commun., 2020, 40: 43-59.

[43] RehmaniHS, IssaevaN. EGFR in head and neck squamous cell carcinoma: exploring possibilities of novel drug combinations. Ann. Transl. Med, 2020, 8813.

[44] KennyPA, BissellMJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J. Clin. Investig., 2007, 117: 337-345.

[45] SuttonP, BorgiaJA, BonomiP. & Plate, J. M. D. Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells. Mol. Cancer, 2013, 1276.

[46] de HeerEC, JalvingM, HarrisAL. HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. J. Clin. Investig., 2020, 130: 5074-5087.

[47] FranovicA, et al.. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc. Natl Acad. Sci. USA, 2007, 104: 13092-13097.

[48] WangY, et al.. Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. Proc. Natl Acad. Sci. USA, 2012, 109: 4892-4897.

[49] PascoluttiR, et al.. Molecularly distinct clathrin-coated pits differentially impact EGFR fate and signaling. Cell Rep., 2019, 27: 3049-3061.e3046.

[50] KroemerG, MariñoG, LevineB. Autophagy and the integrated stress response. Mol. Cell, 2010, 40: 280-293.

[51] WuM, ZhangP. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Cancer Lett., 2020, 469: 207-216.

[52] BaoX, et al.. Proteolytic release of the p75(NTR) intracellular domain by ADAM10 promotes metastasis and resistance to anoikis. Cancer Res., 2018, 78: 2262-2276.

[53] LiaoHW, et al.. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J. Clin. Investig., 2015, 125: 4529-4543.

[54] ChakrabortyA, et al.. Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2. Proc. Natl Acad. Sci. USA, 2011, 108: 2205-2209.

[55] LonicA, et al.. Phosphorylation of PKC delta by FER tips the balance from EGFR degradation to recycling. J. Cell Biol., 2021, 220e201902073.

[56] ZhangXW, et al.. Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR. Cell Death Disease, 2022, 1341.

[57] AlwanHAJ, van ZoelenEJJ, van LeeuwenJEM. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J. Biol. Chem., 2003, 278: 35781-35790.

[58] ShiJB, LiuZY, XuQ. Tumor necrosis factor receptor-associated factor 6 contributes to malignant behavior of human cancers through promoting AKT ubiquitination and phosphorylation. Cancer Sci., 2019, 110: 1909-1920.

[59] XuQ, LiuX, ChenW, ZhangZ. Inhibiting adenoid cystic carcinoma cells growth and metastasis by blocking the expression of ADAM 10 using RNA interference. J. Transl. Med., 2010, 8136.

Funding

National Natural Science Foundation of China (National Science Foundation of China)(82273095, 82203614)

the Shanghai Sailing Program (22YF1421600)

RIGHTS & PERMISSIONS

The Author(s)